4 patents
Utility
Genes and gene signatures for diagnosis and treatement of melanoma
5 Dec 23
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
Filed: 20 May 21
Utility
Genes and gene signatures for diagnosis and treatment of melanoma
21 Feb 23
Panels of biomarkers, methods and systems are disclosed for determining gene expression, and diagnosing and treating melanoma.
Michael Bryan Warf, Benjamin Roa, Alexander Gutin, Darl Flake
Filed: 10 Feb 20
Utility
Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma
6 Sep 22
The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.
Robert Willis Cook, Derek Maetzold, Kristen Oeschlager
Filed: 17 Jan 20
Utility
Diagnostic test for predicting metastasis and recurrence in cutaneous melanoma
2 Mar 20
The invention as disclosed herein in encompasses a method for predicting the risk of metastasis of a primary cutaneous melanoma tumor, the method encompassing measuring the gene-expression levels of at least eight genes selected from a specific gene set in a sample taken from the primary cutaneous melanoma tumor; determining a gene-expression profile signature from the gene expression levels of the at least eight genes; comparing the gene-expression profile to the gene-expression profile of a predictive training set; and providing an indication as to whether the primary cutaneous melanoma tumor is a certain class of metastasis or treatment risk when the gene expression profile indicates that expression levels of at least eight genes are altered in a predictive manner as compared to the gene expression profile of the predictive training set.
Robert Willis Cook, Derek Maetzold, Kristen Oeschlager
Filed: 18 Mar 16
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first